|Bid price||128.00||Open price||132.00|
|Ask price||129.25||Prev close||128.00|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||n/a|
|Latest Share Price (p)||128.00||Net Gearing (%)||-0.13|
|Market Capitalisation (£m)||514.67||Gross Gearing (%)||26.40|
|Shares in issue (m)||402.46||Debt Ratio||22.10|
|P/E Ratio||-182.69||Debt-to-Equity Ratio||0.79|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.36|
|Dividend Yield (%)||0.00||Price to book value||2.27|
|Dividend cover (x)||0.00||ROCE||-0.03|
|Earning per share (p)||-0.70||EPS Growth (%)||61.11|
|52 week high / low||171.50 / 113.75||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|08/07/2014||BUY||Dr Christopher Blackwell||CEO||1,212|
|08/07/2014||BUY||Dr Trevor Phillips||ED||1,212|
/* */ RNS Number : 2384A Vectura Group plc 19 December 2014 Vectura Group plc Director declaration Chippenham, UK - 19 December 2014 : In accordance with Listing Rule 9.6.14 (2) Vectura Group plc (LSE:VEC)...
/* */ RNS Number : 6816Z Vectura Group plc 12 December 2014 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST...
Vectura Group has published the results of a clinical study demonstrating positive results from its Phase IIb/III (Acti-AICS-001) clinical trial investigating the efficacy, safety and tolerability of VR475 in the treatment of oral corticosteroid (OCS)-dependent (GINA Step 5) asthma patients....
Register now for FREE Vectura Group company news